Aberrant Diffuse Expression of p63 in Prostate Adenocarcinoma: A Case Report

Faye Victoria Casimero, Jose Jasper Andal, Jeffrey So


We report a rare case of prostatic adenocarcinoma with diffuse aberrant p63 expression in the luminal cells. p63-positive prostatic adenocarcinoma often has distinctive morphology and immunoprofile, but may be confused with benign mimickers of prostate cancer. It is suggested that this tumor variant is molecularly distinct from usual type prostatic adenocarcinoma. Despite sometimes exhibiting seemingly unfavorable Gleason patterns, a less aggressive biologic behavior is often observed. Literature regarding molecular profile, morphologic characteristics, grading, and prognosis of this entity is reviewed.


aberrant, AMACR/HMWCK/p63 cocktail, needle biopsy, prostatic adenocarcinoma, p63

Full Text:

Abstract HTML


Grisanzio C, Signoretti S. p63 in prostate biology and pathology. J Cell Biochem. 2008;103(5): 1354–68. PMID: 17879953. https://doi.org/10.1002/jcb.21555.

Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol. 2007;60(1):35-42. PMID: 17213347. PMCID: PMC1860598. https://doi.org/10.1136/jcp.2005.036442.

Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol. 2008;32(3): 461-7. PMID: 18300803. https://doi.org/10.1097/PAS.0b013e318157020e.

Baydar DE, Kulac I, Gurel B, De Marzo A. A case of prostatic adenocarcinoma with aberrant p63 expression: presentation with detailed immunohistochemical study and FISH analysis. Int J Surg Pathol. 2011;19(1):131-6. PMID: 20719821. https://doi.org/10.1177/1066896910379478.

Wu A, Kunju LP. Prostate cancer with aberrant diffuse p63 expression. Arch Pathol Lab Med. 2013; 137: 1179-84. PMID: 23991727. https://doi.org/10.5858/arpa.2013-0254-CR.

Leung A, Ross F, Roberts M, Watson R, Smith D, Srinivisan B. Aberrant p63 expression in prostate adenocarcinoma: a potential diagnostic pitfall. Pathology. 2017;49(1):S77. https://doi.org/10.1016/j.pathol.2016.12.200.

Giannico GA, Ross HM, Lotan T, Epstein JI. Aberrant expression of p63 in adenocarcinoma of the prostate. Am J Surg Pathol. 2013;37 (9):1401-6. PMID: 23774168. https://doi.org/10.1097/PAS.0b013e31828d5c32.

Epstein JI, Egevad L, Humphrey PA, Montironi R; Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38(8):e6-e19. PMID: 25029122. https://doi.org/10.1097/PAS.0000000000000238.

Signoretti S, Pires MM, Lindauer M, et al. p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A. 2005;102(32):11355-60. PMID: 16051706. PMCID: PMC1183537. https://doi.org/10.1073/pnas.0500165102.

Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 2000;157(6):1769-75. PMID: 11106548. PMCID: PMC1885786. https://doi.org/10.1016/S0002-9440(10)64814-6.

Su X, Chakravati D, Flores ER. p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev Cancer. 2013;13(2):136-43. PMID: 23344544. PMCID: PMC4181578. https://doi.org/10.1038/nrc3446.

Parsons JK, Saria EA, Nakayama M, et al. Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells. Prostate. 2009;69(5):559-69. PMID:19142959. PMCID: PMC2875878. https://doi.org/10.1002/pros.20904.

Tan H, Haffner MC, Esopi DM, et al. Prostate adenocarcinoma aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. Mod Pathol. 2015;28(3):446-56. PMID: 25216229. PMCID: PMC4344845. https://doi.org/10.1038/modpathol.2014.115.

Uchida K, Ross HM, Lotan T, et al. ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. Hum Pathol. 2015 Mar; 46(3):384-9. PMID: 25548110. https://doi.org/10.1016/j.humpath.2014.11.011.

Takahashi H, Fukutome K, Watanabe M, et al. Mutation analysis of the p51 gene and correlation between p53, p73, and p51 expressions in prostatic carcinoma. Prostate. 2001;47(2):85–90. PMID: 11340630. https://doi.org/10.1002/pros.1050.

Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644–8. PMID: 16254181. https://doi.org/10.1126/science.1117679.

Tomlins SA, Rhodes DR, Yu J et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell. 2008;13(6):519–28. PMID: 18538735. PMCID: PMC2732022. https://doi.org/10.1016/j.ccr.2008.04.016.

Krohn A, Diedler T, Burkhardt L, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol. 2012;181(2):401–12. PMID: 22705054. https://doi.org/10.1016/j.ajpath.2012.04.026.

Lee WH, Isaacs WB, Bova GS, Nelson WG. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol Biomark Prev. 1997;6(6):443-50. PMID: 9184779.

Tucci P, Agostini M, Grespi F, et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A. 2012; 109(38):15312-7. PMID: 22949650. PMCID: PMC3458363. https://doi.org/10.1073/pnas.1110977109.

Dhillon PK, Barry M, Stampfer MJ, et al. Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2009;18(2):595–600. PMCID: PMC2692093. NIHMSID: NIHMS107808.

Ferronika P, Triningsih FE, Ghozali A, et al. p63 cytoplasmic aberrance is associated with high prostate cancer stem cell expression. Asian Pac J Cancer Prev. 2013;13(5):1943-8. PMID: 22901151.


  • There are currently no refbacks.